Used in the development of pharmaceuticals targeting respiratory diseases, particularly as a long-acting beta2-adrenergic agonist (LABA) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It functions by relaxing bronchial smooth muscle, leading to improved airflow and reduced symptoms such as wheezing and shortness of breath. Its structural design allows for prolonged duration of action, enabling once-daily dosing in some formulations. Often combined with inhaled corticosteroids in fixed-dose inhalers to provide both bronchodilation and anti-inflammatory effects. Shows high selectivity for beta2-receptors, minimizing cardiovascular side effects. Investigated for potential use in other conditions involving bronchospasm or airway hyperresponsiveness.